ID: ALA497136

Max Phase: Preclinical

Molecular Formula: C23H16N4O5

Molecular Weight: 428.40

Molecule Type: Small molecule

Representations

Synonyms (1): Lavendamycin Beta-Hydroxyethyl Ester
Synonyms from Alternative Forms(1):

Canonical SMILES:  NC1=CC(=O)c2ccc(-c3nc(C(=O)OCCO)cc4c3[nH]c3ccccc34)nc2C1=O

Standard InChI:  InChI=1S/C23H16N4O5/c24-14-10-18(29)12-5-6-16(26-20(12)22(14)30)21-19-13(11-3-1-2-4-15(11)25-19)9-17(27-21)23(31)32-8-7-28/h1-6,9-10,25,28H,7-8,24H2

Standard InChI Key:  CZOSRJQATJYCOK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 428.40

Molecular Weight (Monoisotopic): 428.1121

AlogP: 2.15

#Rotatable Bonds: 4

Polar Surface Area: 148.26

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.41

CX Basic pKa: 0.19

CX LogP: 1.32

CX LogD: 1.32

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.42

Np Likeness Score: 0.64

References

1. Hassani M, Cai W, Koelsch KH, Holley DC, Rose AS, Olang F, Lineswala JP, Holloway WG, Gerdes JM, Behforouz M, Beall HD..  (2008)  Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.,  51  (11): [PMID:18457384] [10.1021/jm701066a]

Source

Source(1):

• Scientific Literature